Entering text into the input field will update the search result below

Karyopharm sinks on setback for U.S. label expansion of cancer therapy

Mar. 02, 2022 8:23 AM ETKaryopharm Therapeutics Inc. (KPTI)By: Dulan Lokuwithana, SA News Editor2 Comments

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

The shares of the commercial-stage biotech, Karyopharm Therapeutics (NASDAQ:KPTI) have lost ~28% in the pre-market Wednesday amid concerns that the company will need another trial to support its request for U.S. label expansion of

Recommended For You

Comments (2)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

prudent 576 profile picture
Another set back, but the FDA seems to have shown KPTI the way to label expansion for Xpovio. www.youtube.com/...
Glad I exited just under $12. Maybe I will look at these guys again....in 2024.

About KPTI

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Karyopharm Therapeutics Inc.
Immix Biopharma, Inc.
Generation Bio Co.
Rallybio Corporation
Werewolf Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.